Literature DB >> 8508395

Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma.

T E Witzig1, M V Dhodapkar, R A Kyle, P R Greipp.   

Abstract

BACKGROUND: The analysis of peripheral blood mononuclear cells for plasma cells and B-cell surface light chain ratios may provide additional insight on the pathogenesis of multiple myeloma and predict disease activity. The goals of this study were to correlate these parameters with clinically determined disease activity and establish a cutoff value of circulating plasma cells that could be used in future clinical trials.
METHODS: Peripheral blood samples from 84 patients with monoclonal gammopathies were analyzed by an immunofluorescence, slide-based, labeling index (LI) technique for detection of plasma cells, the LI, and light chain ratios. These parameters were compared with disease activity.
RESULTS: Of the 84 patients studied, 27% had inactive and 73% had active disease. The mean number of plasma cells for patients with inactive disease was 0.61 x 10(6)/l, compared with 139.6 x 10(6)/l for patients with active disease (P < 0.001). The mean ratios of involved to uninvolved light chain percentages for patients with inactive and active disease were 1.6 and 9.2, respectively (P = 0.002). The absolute number of plasma cells better predicted disease activity than the light chain ratio. By use of a cutoff value of 3 x 10(6)/l, 67% of patients with active disease were determined to have 3 x 10(6)/l or more plasma cells, and 96% of those with inactive disease had less than 3 x 10(6)/l plasma cells.
CONCLUSIONS: These results suggest that detection of circulating plasma cells is a marker of disease activity in patients with plasma cell disorders and that an appropriate cutoff value is 3 x 10(6)/l or more circulating plasma cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8508395     DOI: 10.1002/1097-0142(19930701)72:1<108::aid-cncr2820720121>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis.

Authors:  Roshini S Abraham; Michelle K Manske; Neta S Zuckerman; Abhishek Sohni; Hanna Edelman; Gitit Shahaf; Michael M Timm; Angela Dispenzieri; Morie A Gertz; Ramit Mehr
Journal:  J Clin Immunol       Date:  2006-12-28       Impact factor: 8.317

2.  Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.

Authors:  W I Gonsalves; S V Rajkumar; V Gupta; W G Morice; M M Timm; P P Singh; A Dispenzieri; F K Buadi; M Q Lacy; P Kapoor; M A Gertz; S K Kumar
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 11.528

3.  Quantification of clonal circulating plasma cells in relapsed multiple myeloma.

Authors:  Wilson I Gonsalves; William G Morice; Vincent Rajkumar; Vinay Gupta; Michael M Timm; Angela Dispenzieri; Francis K Buadi; Martha Q Lacy; Preet P Singh; Prashant Kapoor; Morie A Gertz; Shaji K Kumar
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

4.  Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system.

Authors:  David Dingli; Grzegorz S Nowakowski; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; S Vincent Rajkumar; Philip R Greipp; Mark R Litzow; Dennis A Gastineau; Thomas E Witzig; Morie A Gertz
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

Review 5.  Immunophenotyping in multiple myeloma and related plasma cell disorders.

Authors:  Shaji Kumar; Teresa Kimlinger; William Morice
Journal:  Best Pract Res Clin Haematol       Date:  2010-09       Impact factor: 3.020

6.  A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis.

Authors:  Nagaaki Katoh; Tanya L Poshusta; Michelle K Manske; Angela Dispenzieri; Morie A Gertz; Roshini S Abraham; Marina Ramirez-Alvarado
Journal:  J Clin Immunol       Date:  2011-09-10       Impact factor: 8.317

7.  Detection and characterization of plasma cells in peripheral blood: correlation of IgE+ plasma cell frequency with IgE serum titre.

Authors:  A Horst; N Hunzelmann; S Arce; M Herber; R A Manz; A Radbruch; R Nischt; J Schmitz; M Assenmacher
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

8.  Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.

Authors:  Rehan Khan; Nidhi Gupta; Raman Kumar; Manoj Sharma; Lalit Kumar; Alpana Sharma
Journal:  Clin Exp Metastasis       Date:  2014-05-08       Impact factor: 5.150

9.  Identification of malignant cells in multiple myeloma bone marrow with immunoglobulin VH gene probes by fluorescent in situ hybridization and flow cytometry.

Authors:  J Cao; R A Vescio; C H Hong; A Kim; A K Lichtenstein; J R Berenson
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

10.  Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management.

Authors:  María A Vasco-Mogorrón; José A Campillo; Adela Periago; Valentin Cabañas; Mercedes Berenguer; María C García-Garay; Lourdes Gimeno; María F Soto-Ramírez; María D Martínez-Hernández; Manuel Muro; Alfredo Minguela
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.